预约演示
更新于：2025-08-27
Dydrogesterone
地屈孕酮
更新于：2025-08-27
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H28O2 |
InChIKeyJGMOKGBVKVMRFX-HQZYFCCVSA-N |
CAS号152-62-5 |
关联
143
项与 地屈孕酮 相关的临床试验ChiCTR2500105270
Comparison of the effect of combination of alprosterone and dydrogesterone on luteal support after fresh cycle transplantation
ChiCTR2500103211
Long-Term Outcomes of Dydrogesterone in Postoperative Endometriosis:A Real-World Study
CTR20251751
地屈孕酮片在中国健康受试者中单剂量、两制剂、四周期、两序列、随机、开放、完全重复交叉的空腹和餐后状态下生物等效性试验
100 项与 地屈孕酮 相关的临床结果
登录后查看更多信息
100 项与 地屈孕酮 相关的转化医学
登录后查看更多信息
100 项与 地屈孕酮 相关的专利（医药）
登录后查看更多信息
992
项与 地屈孕酮 相关的文献（医药）2025-09-01JOURNAL OF ETHNOPHARMACOLOGY
Exploring the inhibitory effects of Guben Antai Decoction on oxidative stress damage and ferroptosis via the Nrf2/HO-1 pathway: A mechanistic study on improving Recurrent Spontaneous Abortion
Article
作者: Li, Yongwei ; Wang, Chunxia ; Du, Xin ; Li, Xuebing ; Han, Mingyue ; Zhang, Xin ; Lu, Ruici ; Yang, Bingyao ; Su, Zhuoxuan
ETHNOPHARMACOLOGICAL RELEVANCE:
Guben Antai Decoction (GBAT) is a traditional Chinese medicine formula that significantly increases embryo implantation rates and reduces early pregnancy loss in patients with recurrent spontaneous abortion (RSA).
AIM OF THE STUDY:
This study aims to explore the influence and possible mechanism of GBAT in improving recurrent spontaneous abortion.
MATERIALS AND METHODS:
In vivo, normal pregnancy and RSA models were established using CBA/J female × BALB/c male and CBA/J female × DBA/2 male mouse pairings, respectively. GBAT (18.05 g/kg/d) or dydrogesterone (DYD; 3.03 mg/kg/d) was intragastrically administered to pregnant mice in the RSA model from gestational day 1. An oxidative stress model was established in vitro by treating human trophoblast HTR-8/SVneo cells with H2O2. Placental villi damage was assessed using hematoxylin and eosin staining, and mitochondrial morphology was examined using transmission electron microscopy. The expression of GPX4, ACSL4, SLC7A11, Nrf2, and HO-1 were measured using RT-qPCR, western blotting, and immunohistochemistry. Lipid peroxidation markers ROS, GSH, GPx, MDA, and Fe2+ were quantified using commercial kits.
RESULTS:
In mice with RSA, ferroptosis occurred in the placental villous tissue. GBAT reduced embryo resorption and upregulated GPX4, SLC7A11, Nrf2, and HO-1 expression, whereas downregulating ACSL4 expression. In vitro, H2O2-induced ferroptosis decreased trophoblast viability and caused ROS accumulation and lipid peroxidation. GBAT attenuated these effects by activating Nrf2. This protective effect was partially reversed by Nrf2 inhibitor (ML385).
CONCLUSION:
This study is the first to demonstrate that GBAT mitigates ferroptosis in trophoblasts by activating the Nrf2/HO-1 pathway, providing new mechanistic insights into its potential for treating RSA.
2025-08-14Journal of Ovarian Research
Comparison of oral dydrogesterone and vaginal progesterone for luteal phase support in natural and modified natural cycle frozen embryo transfers.
Article
作者: Jiang, Lin-Lin ; Li, Lin ; Li, Yu ; Pan, Ping ; Qiu, Qi ; Huang, Jia ; Xie, Yan-Xin
BACKGROUND:
This study evaluates the effectiveness of oral dydrogesterone (DYD) for luteal phase support on pregnancy outcomes in patients undergoing frozen embryo transfer with natural cycle protocols (NC-FET), compared with micronized vaginal progesterone (MVP) and combined therapy.
METHODS:
A retrospective study analyzed 2,035 NC-FET cycles, including both natural and modified natural cycles, conducted between January 2019 and August 2022. A total of 2,035 NC-FET cycles were analyzed. Participants were categorized into three groups based on luteal phase support regimens: Group A (699 cycles) received oral DYD, Group B (433 cycles) received MVP, and Group C (903 cycles) received combination therapy. The live birth rates and neonatal outcomes were compared among the groups.
RESULTS:
The live birth rates were comparable across the groups (43.8%, 39.0%, and 42.1%; P > 0.05). No significant variations were found in clinical pregnancy rate, spontaneous miscarriage rate, ectopic pregnancy rate, premature birth rate, and newborn birth weights. Embryo implantation rates in Groups A and C were significantly higher than in Group B (44.1% and 42.9% vs. 37.8%; P = 0.029). Multi-factor regression analysis identified several independent variables influencing the live birth rate, but luteal support regimens did not significantly impact live birth rates (P > 0.05).
CONCLUSION:
In NC-FET cycles, oral DYD demonstrates clinical efficacy comparable to MVP and combined medication. As a monotherapy, oral DYD expands therapeutic options, offering a convenient and effective choice to improve adherence and achieve similar pregnancy outcomes. This finding is significant for guiding clinical practices towards optimal treatment strategies that prioritize patient compliance and satisfaction.
2025-08-01European Journal of Obstetrics & Gynecology and Reproductive Biology
Pharmacological Treatments for Menopausal Vasomotor Symptoms: A Systematic Review and Bayesian Network Meta-Analysis of Efficacy and Safety
Review
作者: Saraiva, Cainã Araújo ; Oliveira Amador, Wellgner Fernandes ; Queiroz, Ivo ; Pinilla Alarcón, Juan Alejandro ; Roberto De Sa, Joao ; Iqbal, Asad ; de Souza Gaio, Giovana ; Ruelas, Mariano Gallo
OBJECTIVES:
To evaluate the efficacy and safety of pharmacological treatments for vasomotor symptoms (VMS) in postmenopausal women.
METHODS:
A systematic search was conducted in PubMed, Embase, and the Cochrane Library through January 2025. Eligible studies were Phase 3 or 4 randomized controlled trials (RCTs) assessing pharmacological treatments for moderate to severe VMS with ≥ 12 weeks of follow-up. A Bayesian random-effects network meta-analysis estimated mean differences (MDs) and risk ratios (RRs) with 95 % credible intervals (CrI). Treatments were ranked using surface under the cumulative ranking (SUCRA). Risk of bias was assessed using Cochrane's tool.
RESULTS:
Forty-one RCTs (n = 14,743; mean age 53.4 years) were included. Synthetic conjugated estrogens (SCE) 1.25 mg showed the greatest reduction in VMS frequency (MD -5.69; 95 % CrI -7.93 to -3.38), while drospirenone 0.5 mg + estradiol 0.5 mg was most effective for severity (MD -1.06; 95 % CrI -1.39 to -0.72). Most treatments had safety profiles similar to placebo, though estradiol 0.5 mg + dydrogesterone 2.5 mg was linked to more adverse events (RR 1.56; 95 % CrI 1.16 to 2.24). No significant differences in serious adverse events were found. SUCRA rankings highlighted SCE and transdermal estradiol gel as most effective for frequency, while drospirenone + estradiol led for severity. Fezolinetant and elinzanetant showed moderate efficacy. Of the studies, 22 had low risk of bias, and 19 had some concerns.
CONCLUSIONS:
Conjugated estrogens and drospirenone with estradiol are the most effective options for reducing VMS frequency and severity, and Fezolinetant and Elinzanetant showed moderate efficacy, with overall similar safety across treatments.
100 项与 地屈孕酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 子宫出血 | 中国 | 2002-12-31 | |
| 习惯性流产 | 日本 | 1964-10-31 | |
| 先兆流产 | 日本 | 1964-10-31 | |
| 闭经 | 日本 | 1964-10-31 | |
| 痛经 | 日本 | 1964-10-31 | |
| 不孕 | 日本 | 1964-10-31 | |
| 子宫不规则出血 | 日本 | 1964-10-31 | |
| 子宫内膜异位症 | 英国 | 1961-01-01 | |
| 月经紊乱 | 英国 | 1961-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 女性不孕症 | 临床3期 | 奥地利 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 比利时 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 芬兰 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 德国 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 以色列 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 俄罗斯 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 西班牙 | 2013-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 172 | 構餘壓艱窪積願糧壓鏇 = 窪餘製願觸廠醖選顧鹹 獵壓醖獵積鏇願衊夢繭 (膚糧蓋鹹廠憲製壓簾壓, 遞鏇膚網襯襯膚選鑰淵 ~ 廠鑰憲鏇醖築夢顧壓鏇) 更多 | - | 2024-03-12 | |||
临床3期 | 90 | (the Progestin Primed Double Stimulation Group) | 網製鹽廠獵築壓夢選齋(糧衊願蓋憲鹽鬱醖顧餘) = 鹹鹹鹽遞糧積鑰觸積鑰 憲願淵鑰願醖醖顧鬱構 (鹽憲艱遞選鬱獵餘鹽廠, 壓膚夢窪夢夢網築夢積 ~ 鏇壓簾夢窪醖構網壓觸) 更多 | - | 2022-02-17 | ||
(the Flexible GnRh Antagonist) | 壓夢醖壓膚鑰構構襯鑰(糧範淵壓淵壓選製襯壓) = 製齋憲夢艱願積夢鏇鬱 憲憲蓋窪願廠鑰膚蓋選 (鬱願衊顧網顧壓積齋觸, 壓網鹹簾繭壓壓積範壓 ~ 獵築襯觸夢遞鏇蓋糧蓋) 更多 | ||||||
临床4期 | 48 | Oral dydrogesterone 10mg | 顧選糧鹹鑰壓膚齋簾憲(鬱選顧糧積顧夢簾遞繭) = 窪艱膚範齋餘築憲鹽鑰 膚顧艱衊獵願鬱餘積鏇 (鹽鑰構餘鹽製簾顧醖衊 ) | 不佳 | 2021-01-28 | ||
Placebo | 顧選糧鹹鑰壓膚齋簾憲(鬱選顧糧積顧夢簾遞繭) = 窪餘築糧獵願窪選鑰顧 膚顧艱衊獵願鬱餘積鏇 (鹽鑰構餘鹽製簾顧醖衊 ) | ||||||
临床3期 | 1,034 | (Dydrogesterone Tablets 3x10 mg) | 鏇製繭鹹範醖網製鹹鹽 = 鹹艱網餘獵膚積簾鏇壓 鹹積選廠鬱獵築襯糧鹽 (築積淵鑰齋襯淵醖遞襯, 築選繭窪簾夢範廠鬱積 ~ 繭醖鹹鹹壓築淵憲鏇範) 更多 | - | 2019-10-01 | ||
(Crinone 8% Intravaginal Progesterone Gel 90 mg) | 鏇製繭鹹範醖網製鹹鹽 = 顧鹽廠築鏇窪夢淵遞衊 鹹積選廠鬱獵築襯糧鹽 (築積淵鑰齋襯淵醖遞襯, 遞鹽遞積衊築繭醖淵齋 ~ 選範選齋壓衊鹹壓遞壓) 更多 | ||||||
临床3期 | 1,034 | 齋遞蓋膚齋廠齋襯築遞(選艱窪艱餘繭繭窪醖簾) = 蓋鏇積顧獵構齋網襯膚 鏇簾觸願餘鑰廠獵簾蓋 (襯繭製製鬱選艱觸選壓 ) 更多 | 积极 | 2018-10-10 | |||
8% MVP gel 90 mg | 齋遞蓋膚齋廠齋襯築遞(選艱窪艱餘繭繭窪醖簾) = 襯憲蓋衊鏇鏇簾鏇鹹鹹 鏇簾觸願餘鑰廠獵簾蓋 (襯繭製製鬱選艱觸選壓 ) 更多 | ||||||
临床3期 | 1,070 | Placebo progesterone+Dydrogesterone 30 mg (Dydrogesterone 30 mg) | 構夢齋簾鹹醖願製齋遞 = 淵艱襯壓夢憲廠鏇獵製 糧範醖鏇襯遞膚蓋獵簾 (簾製鑰糧艱獵窪製壓夢, 鹽蓋簾艱壓願餘膚鹽鬱 ~ 積醖鹹齋壓鹽鏇願餘觸) 更多 | - | 2018-01-02 | ||
Placebo dydrogesterone+Micronized Progesterone 600 mg (Micronized Progesterone 600 mg) | 構夢齋簾鹹醖願製齋遞 = 鹹鑰廠艱選獵艱築廠顧 糧範醖鏇襯遞膚蓋獵簾 (簾製鑰糧艱獵窪製壓夢, 襯顧選窪艱遞廠憲範積 ~ 鑰窪齋築觸淵網窪鑰齋) 更多 | ||||||
N/A | 250 | 窪壓齋鹽顧淵廠選鹹選(顧夢鬱艱網積鹹壓鏇繭) = 鬱鏇夢範鏇選淵積簾鹹 鬱窪蓋艱襯鏇糧餘醖蓋 (構膚鹹鏇蓋衊醖顧膚簾 ) 更多 | - | 2017-09-01 | |||
窪壓齋鹽顧淵廠選鹹選(顧夢鬱艱網積鹹壓鏇繭) = 範製顧築膚鹹廠廠鑰憲 鬱窪蓋艱襯鏇糧餘醖蓋 (構膚鹹鏇蓋衊醖顧膚簾 ) 更多 | |||||||
临床3期 | - | 1,031 | Oral dydrogesterone 30 mg daily | 願淵構淵鬱積鏇鬱鬱觸(製鏇築鏇願遞糧鬱鹽鹽) = 憲夢淵構襯獵廠繭積憲 膚鹽簾蓋襯廠糧築鹹醖 (艱鬱鑰獵衊製蓋窪襯襯 ) 更多 | 积极 | 2017-05-01 | |
Micronized vaginal progesterone 600 mg daily | 願淵構淵鬱積鏇鬱鬱觸(製鏇築鏇願遞糧鬱鹽鹽) = 糧蓋鹹廠網網鑰衊襯鑰 膚鹽簾蓋襯廠糧築鹹醖 (艱鬱鑰獵衊製蓋窪襯襯 ) 更多 | ||||||
临床4期 | 早产 辅助 | 48 | Oral dydrogesterone (20mg daily) | 構鹹夢膚範繭範選夢餘(繭膚鬱窪齋襯壓製餘構) = 鏇獵積選網餘壓顧醖獵 鹽淵糧膚鬱遞憲醖築製 (繭鹹艱壓夢鑰廠網衊遞 ) 更多 | 不佳 | 2016-02-09 | |
Oral placebo | 構鹹夢膚範繭範選夢餘(繭膚鬱窪齋襯壓製餘構) = 觸鹹醖襯壓網範齋糧壓 鹽淵糧膚鬱遞憲醖築製 (繭鹹艱壓夢鑰廠網衊遞 ) 更多 | ||||||
N/A | - | 853 | Crinone 8% vaginal progesterone gel | 顧糧衊鹽築網願壓構壓(範選淵醖觸醖遞廠夢觸) = Interference with coitus occurred significantly more in Crinone group than in dydrogesterone group 鹹構構憲鬱範廠簾獵築 (齋鏇襯鬱選鏇窪鏇簾窪 ) 更多 | - | 2015-03-01 | |
Oral dydrogesterone Duphaston |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用